BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
BioNTech puts a ring on Biotheus
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
